Terms: = Prostate cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF
1446 results:
1. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
2. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract] [Full Text] [Related]
3. Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics.
Hu B; Wang C; Wu Y; Han C; Liu J; Chen R; Wang T
J Ethnopharmacol; 2024 Aug; 330():118228. PubMed ID: 38643863
[TBL] [Abstract] [Full Text] [Related]
4. [Pesticide exposure and chronic respiratory diseases].
Jestin-Guyon N; Raherison-Semjen C
Rev Mal Respir; 2024 May; 41(5):343-371. PubMed ID: 38594123
[TBL] [Abstract] [Full Text] [Related]
5. Current Systemic Therapy in Men with Metastatic Castration-Sensitive prostate cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract] [Full Text] [Related]
6. Current Trends and Challenges of Microbiome Research in prostate cancer.
Trecarten S; Fongang B; Liss M
Curr Oncol Rep; 2024 May; 26(5):477-487. PubMed ID: 38573440
[TBL] [Abstract] [Full Text] [Related]
7. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G; Malek R; Mannuel H; Hussain A
Curr Opin Oncol; 2024 May; 36(3):195-201. PubMed ID: 38573209
[TBL] [Abstract] [Full Text] [Related]
8. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract] [Full Text] [Related]
9. Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.
Einstein DJ; Aragon-Ching JB; Karzai F; Madan RA
Curr Opin Oncol; 2024 May; 36(3):164-168. PubMed ID: 38573205
[TBL] [Abstract] [Full Text] [Related]
10. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment.
He Y; Yu Q; Ma X; Lv D; Wang H; Qiu W; Chen XF; Jiao Y; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118075. PubMed ID: 38513779
[TBL] [Abstract] [Full Text] [Related]
11. Printing of 3D biomimetic structures for the study of bone metastasis: A review.
Khanmohammadi M; Volpi M; Walejewska E; Olszewska A; Swieszkowski W
Acta Biomater; 2024 Apr; 178():24-40. PubMed ID: 38458512
[TBL] [Abstract] [Full Text] [Related]
12. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract] [Full Text] [Related]
13. Optimal systemic therapy in men with low-volume prostate cancer.
Saxena A; Andrews J; Bryce AH; Riaz IB
Curr Opin Urol; 2024 May; 34(3):183-197. PubMed ID: 38445371
[TBL] [Abstract] [Full Text] [Related]
14. Metastasis-directed therapy in oligometastatic prostate cancer.
Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
[TBL] [Abstract] [Full Text] [Related]
15. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
16. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.
Paindelli C; Parietti V; Barrios S; Shepherd P; Pan T; Wang WL; Satcher RL; Logothetis CJ; Navone N; Campbell MT; Mikos AG; Dondossola E
Acta Biomater; 2024 Apr; 178():83-92. PubMed ID: 38387748
[TBL] [Abstract] [Full Text] [Related]
17. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in prostate cancer.
Sentana-Lledo D; Morgans AK
Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
[TBL] [Abstract] [Full Text] [Related]
18. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
Chen H; Dong K; Ding J; Xia J; Qu F; Lan F; Liao H; Qian Y; Huang J; Xu Z; Gu Z; Shi B; Yu M; Cui X; Yu Y
Cancer Lett; 2024 Apr; 587():216725. PubMed ID: 38364963
[TBL] [Abstract] [Full Text] [Related]
19. Stereotactic ablative radiation therapy in metastatic prostate cancer.
Bazyar S; Mannuel H; Tran PT
Curr Opin Oncol; 2024 May; 36(3):180-185. PubMed ID: 38362949
[TBL] [Abstract] [Full Text] [Related]
20. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract] [Full Text] [Related]
[Next]